Table 1 Correlation between the expression of stathmin1 and clinical classification in gastric cancer

From: Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells

 

Immunoreactivity case No. (%)

 

Clinical classification

Total

Negative

Positive

P -value*

Age at surgery (years)

0.202

 <60

120

60 (50.0)

60 (50.0)

 

 60⩽, <70

68

25 (36.7)

43 (63.3)

 

 70⩽

38

16 (42.1)

22 (57.9)

 

Gender (diffuse type)

0.628

 Male

43

31 (72.1)

12 (27.9)

 

 Female

51

39 (76.5)

12 (23.5)

 

Gender (intestinal type)

0.464

 Male

105

24 (22.9)

81 (77.1)

 

 Female

27

8 (29.6)

19 (70.4)

 

N stages (diffuse type)

0.008

 N0∼N1

70

57 (81.4)

13 (18.6)

 

 N2–N3

24

13 (54.2)

11 (45.8)

 

N stages (intestinal type)

1.000

 N0∼N1

116

27 (23.3)

89 (76.7)

 

 N2–N3

16

4 (25.0)

12 (75.0)

 

TNM stage (diffuse type)

0.005

 1∼2

58

49 (84.5)

9 (15.5)

 

 3∼4

36

21 (58.3)

15 (41.7)

 

TNM stage (intestinal type)

0.946

 1∼2

107

25 (23.4)

82 (76.6)

 

 3∼4

25

6 (24.0)

19 (76.0)

 

Vascular invasion (diffuse type)

0.006

 Negative

61

51 (83.6)

10 (16.4)

 

 Positive

33

19 (57.6)

14 (42.4)

 

Vascular invasion (intestinal type)

0.634

 Negative

98

22 (22.4)

76 (77.6)

 

 Positive

34

9 (26.5)

25 (73.5)

 
  1. Abbreviation: TNM=The tumour-node-metastasis staging system. *P<0.05 was defined as significant, Fisher's exact test.